An open, multicentre, comparative study of the efficacy and safety of azithromycin and co-amoxiclav in the treatment of upper and lower respiratory tract infections in children

被引：7

作者：

Lauvau, DVA ^{[1
]}

Verbist, L ^{[1
]}

Abrassart, C ^{[1
]}

Adriaens, F ^{[1
]}

Andre, F ^{[1
]}

Bockaert, K ^{[1
]}

Bodart, E ^{[1
]}

Bricteux, G ^{[1
]}

Casneuf, J ^{[1
]}

Cassiers, M ^{[1
]}

Chefneux, A ^{[1
]}

DeNayer, J ^{[1
]}

Dechamps, L ^{[1
]}

Deurinck, M ^{[1
]}

Devriendt, E ^{[1
]}

Dockx, M ^{[1
]}

Ehrentreich, U ^{[1
]}

Fafchamps, Y ^{[1
]}

Geuens, M ^{[1
]}

Hecquet, T ^{[1
]}

Hendrickx, G ^{[1
]}

Israel, E ^{[1
]}

Jadoul, R ^{[1
]}

Krygier, A ^{[1
]}

Lagasse, E ^{[1
]}

Lamotte, PJ ^{[1
]}

Legrand, B ^{[1
]}

Lemahieu, R ^{[1
]}

Malchair, R ^{[1
]}

Maquet, JC ^{[1
]}

Mertens, G ^{[1
]}

Neufcoeur, JP ^{[1
]}

Pieraert, C ^{[1
]}

Pierquin, G ^{[1
]}

Prudhomme, J ^{[1
]}

Reginster, L ^{[1
]}

Ureel, D ^{[1
]}

VanBiervliet, JP ^{[1
]}

VanDenNoortgaete, M ^{[1
]}

VanMelkebeke, E ^{[1
]}

Vandenbossche, L ^{[1
]}

Verboven, M ^{[1
]}

Vertruyen, A ^{[1
]}

Zasinska, E ^{[1
]}

Zeligzon, A ^{[1
]}

机构：

[1] ALGEMEEN ZIEKENHUIS ST VINCENTIUS, GHENT, BELGIUM

来源：

JOURNAL OF INTERNATIONAL MEDICAL RESEARCH | 1997年 / 25卷 / 05期

关键词：

azithromycin; co-aimoxiclav; antibacterial; streptococcal pharyngitis; tonsillitis; bronchitis; pneumonia; children;

D O I：

10.1177/030006059702500506

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

An open prospective, multicentre, comparative, randomized (2:1) study was conducted in 481 children diagnosed as having mild-to-moderate lower respiratory tract infections. The efficacy and safety of azithromycin suspension (10 mg/kg), dosed orally once daily for 3 days, was compared with that of co-amoxiclav (10 mg/kg in a 4:1 ratio), dosed orally three times daily for 5 - 10 days. The proportion of evaluable patients (n = 472) showing a cure or improvement was significantly higher in the azithromycin group (96.8%) than in the co-amoxiclav group (91%, P = 0.0199). There were six relapses in both groups, giving an overall response rate of 95% for azithromycin versus 87.1% for co-amoxiclav (P = 0.0025). Adverse events were reported in 10% of the patients treated with azithromycin, and 11.3% of co-amoxiclav patients. Reported and counted compliance was significantly better in the azithromycin group. A 3-day regimen of azithromycin was as effective and as safe as a 5 - 10 day regimen of co-amoxiclav in the treatment of respiratory tract infections in children, and compliance was improved.

引用

页码：285 / 295

页数：11

共 50 条

[21] Once-daily, 3-day azithromycin versus a three-times-daily, 10-day course of co-amoxiclav in the treatment of adults with lower respiratory tract infections: Results of a randomized, double-blind comparative study
Gris, P
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1996, 37 : 93 - 101
[22] SAFETY AND EFFECTIVENESS OF AZITHROMYCIN IN THE TREATMENT OF LOWER RESPIRATORY INFECTIONS: AN INTERNATIONAL, MULTICENTER, NON-COMPARATIVE STUDY
Gasparic, Maja
Penezic, Ana
Kolumbic-Lakos, Adela
Kovacic, Drazen
Kukuruzovic, Mirjana Matrapazovski
Barsic, Bruno
ACTA CLINICA CROATICA, 2015, 54 (02) : 149 - 158
[23] Safety and effectiveness of azithromycin in the treatment of respiratory infections in children
Lakos, Adela Kolumbic
Pangercic, Ana
Gasparic, Maja
Kukuruzovic, Mirjana Matrapazovski
Kovacic, Drazen
Barsic, Bruno
CURRENT MEDICAL RESEARCH AND OPINION, 2012, 28 (01) : 155 - 162
[24] Meta-analysis of randomized controlled trials on the comparative efficacy and safety of azithromycin against other antibiotics for upper respiratory tract infections
Ioannidis, JPA
Contopoulos-Ioannidis, DG
Chew, P
Lau, J
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2001, 48 (05) : 677 - 689
[25] A comparative study of the etiology of adult upper and lower respiratory tract infections in the community
Lieberman, D
Lieberman, D
Korsonsky, I
Ben-Yaakov, M
Lazarovich, Z
Friedman, MG
Dvoskin, B
Leinonen, M
Ohana, B
Boldur, I
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2002, 42 (01) : 21 - 28
[26] Randomized, double-blind study of the clinical efficacy of 3 days of azithromycin compared with co-amoxiclav for the treatment of acute otitis media
Dunne, MW
Latiolais, T
Lewis, B
Pistorius, B
Bottenfield, G
Moore, WH
Garrett, A
Stewart, TD
Aoki, J
Spiegel, C
Boettger, D
Shemer, A
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2003, 52 (03) : 469 - 472
[27] CLINICAL COMPARATIVE-STUDY OF AZITHROMYCIN VERSUS ERYTHROMYCIN IN THE TREATMENT OF ACUTE RESPIRATORY-TRACT INFECTIONS IN CHILDREN
MANFREDI, R
MANTERO, E
SCHIAVONE, R
PAVESIO, D
JANNUZZI, C
LONGO, L
TEMPESTA, A
PECCO, P
CHIODO, F
JOURNAL OF CHEMOTHERAPY, 1992, 4 (06) : 364 - 370
[28] Comparative efficacy and safety of co-amoxiclav, cefpodoxime proxetil, and levofloxacin in patients with acute uncomplicated bacterial tonsillitis: A prospective, open-label, parallel group study
Xaviar, Suja
Girish, K.
Jagannath, B.
Das, Saibal
Joseph, Probin
JOURNAL OF FAMILY MEDICINE AND PRIMARY CARE, 2024, 13 (12) : 5570 - 5574
[29] EFFICACY AND SAFETY OF PIDOTIMOD IN THE PREVENTION OF RECURRENT RESPIRATORY INFECTIONS IN CHILDREN: A MULTICENTRE STUDY
Namazova-Baranova, L. S.
Alekseeva, A. A.
Kharit, S. M.
Kozhevnikova, T. N.
Taranushenko, T. E.
Tuzankina, I. A.
Scarci, F.
INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY, 2014, 27 (03) : 413 - 419
[30] Assessment of the efficacy and safety of paracetamol, ibuprofen and nimesulide in children with upper respiratory tract infections
Ulukol, B
Köksal, Y
Cin, S
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1999, 55 (09) : 615 - 618

← 1 2 3 4 5 →